{
  "docId": "019de073-bad9-7032-8a81-e4ebe475dedb",
  "docSlug": "033dbe0b064db9b5c6a8c7c8096ccb5c",
  "documentTitle": "Genprex | Investor Presentation Deck | 44 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 44,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Clinical trial methodology slide detailing study design and endpoints for two phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bad9-7032-8a81-e4ebe475dedb/22",
  "deckHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb",
  "deckJsonHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb.json",
  "deckAnchorHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.96,
        "x": 0.02,
        "y": 0.55
      },
      "kind": "list",
      "text": "PHASE 2 COMPONENT: Randomized 2:1, open-label, 2-arm study of REQORSA in combination with Keytruda vs. docetaxel +/- ramucirumab; Primary Endpoint: Progression free survival (PFS), PFS improvement; Secondary Endpoints: Overall response rate, Overall survival, Disease control rate, Tolerability, Number of adverse events",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "507f60de-aa5b-40ca-b331-c2bcec229d18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.96,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "list",
      "text": "PHASE 1 COMPONENT: 3+3 dose escalation of REQORSA in combination with Keytruda; Primary Endpoint: Dose limiting toxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ff54f9a-65e8-4b71-9cd9-b1cc19bf582b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.36,
        "y": 0.05
      },
      "kind": "title",
      "text": "Acclaim · 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c56afe0-dc6d-43cf-a812-fa59d7a79cd0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}